NasdaqCM - Nasdaq Real Time Price USD

BioXcel Therapeutics, Inc. (BTAI)

1.5300
-0.0500
(-3.16%)
At close: May 9 at 4:00:00 PM EDT
1.6000
+0.07
+(4.58%)
After hours: May 9 at 6:55:40 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,266
2,266
1,380
375
0
Cost of Revenue
2,143
2,143
1,260
20
0
Gross Profit
123
123
120
355
0
Operating Expense
64,927
64,927
167,739
160,000
106,936
Operating Income
-64,804
-64,804
-167,619
-159,645
-106,936
Net Non Operating Interest Income Expense
-12,527
-12,527
-7,665
-5,685
4
Other Income Expense
17,732
17,732
-3,769
-427
--
Pretax Income
-59,599
-59,599
-179,053
-165,757
-106,932
Net Income Common Stockholders
-59,599
-59,599
-179,053
-165,757
-106,931
Diluted NI Available to Com Stockholders
-59,599
-59,599
-179,053
-165,757
-106,931
Basic EPS
-32.64
-23.51
-98.33
-94.72
-64.80
Diluted EPS
-32.64
-23.51
-98.33
-94.72
-64.80
Basic Average Shares
2,234.3270
2,535
1,821
1,750.9370
1,648.3120
Diluted Average Shares
2,234.3270
2,535
1,821
1,750.9370
1,648.3120
Total Operating Income as Reported
-67,245
-67,245
-171,782
-159,645
-106,935
Total Expenses
67,070
67,070
168,999
160,020
106,936
Net Income from Continuing & Discontinued Operation
-59,599
-59,599
-179,053
-165,757
-106,931
Normalized Income
-57,158
-57,158
-174,890
-165,757
-106,931
Interest Income
2,602
2,602
5,649
2,528
44
Interest Expense
15,129
15,129
13,314
8,213
40
Net Interest Income
-12,527
-12,527
-7,665
-5,685
4
EBIT
-44,470
-44,470
-165,739
-157,544
-106,892
EBITDA
-44,161
-44,161
-165,421
-157,217
-106,595
Reconciled Cost of Revenue
2,143
2,143
1,260
20
0
Reconciled Depreciation
309
309
318
327
297
Net Income from Continuing Operation Net Minority Interest
-59,599
-59,599
-179,053
-165,757
-106,931
Total Unusual Items Excluding Goodwill
-2,441
-2,441
-4,163
0
--
Total Unusual Items
-2,441
-2,441
-4,163
0
--
Normalized EBITDA
-41,720
-41,720
-161,258
-157,217
-106,595
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 3/8/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

KPTI Karyopharm Therapeutics Inc.
6.01
-2.28%
 
CRIS Curis, Inc.
1.8900
-10.00%
 
MRSN Mersana Therapeutics, Inc.
0.3189
-4.81%
 
XFOR X4 Pharmaceuticals, Inc.
3.3700
+2.43%
 
IVVD Invivyd, Inc.
0.6461
+9.51%
 
LPCN Lipocine Inc.
3.2750
-1.65%
 
IGMS IGM Biosciences, Inc.
1.1300
0.00%
 
CRDF Cardiff Oncology, Inc.
2.6600
+1.14%
 
BEIGF BeiGene, Ltd.
15.95
0.00%
 
DWTX Dogwood Therapeutics, Inc.
4.5600
0.00%